Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 42643 | 3.4375 |
09:34 ET | 12505 | 3.42 |
09:36 ET | 5125 | 3.4419 |
09:38 ET | 1460 | 3.455 |
09:39 ET | 2635 | 3.4699 |
09:41 ET | 600 | 3.47 |
09:43 ET | 9107 | 3.435 |
09:45 ET | 1528 | 3.44 |
09:48 ET | 1400 | 3.44 |
09:50 ET | 3914 | 3.4399 |
09:52 ET | 4188 | 3.425 |
09:54 ET | 8953 | 3.435 |
09:56 ET | 1200 | 3.43 |
09:57 ET | 1514 | 3.43 |
09:59 ET | 6324 | 3.44 |
10:01 ET | 17418 | 3.425 |
10:03 ET | 7020 | 3.4375 |
10:06 ET | 2893 | 3.44 |
10:08 ET | 3168 | 3.435 |
10:10 ET | 5801 | 3.435 |
10:12 ET | 326 | 3.44 |
10:14 ET | 1050 | 3.435 |
10:15 ET | 13868 | 3.455 |
10:17 ET | 4049 | 3.4399 |
10:19 ET | 715 | 3.44 |
10:21 ET | 5381 | 3.43 |
10:24 ET | 800 | 3.435 |
10:26 ET | 1732 | 3.435 |
10:28 ET | 200 | 3.435 |
10:30 ET | 11000 | 3.425 |
10:32 ET | 1258 | 3.43 |
10:33 ET | 20575 | 3.435 |
10:35 ET | 6342 | 3.43 |
10:37 ET | 500 | 3.43 |
10:39 ET | 8000 | 3.4201 |
10:42 ET | 1210 | 3.42 |
10:44 ET | 5883 | 3.415 |
10:46 ET | 304 | 3.415 |
10:48 ET | 3455 | 3.43 |
10:50 ET | 538 | 3.43 |
10:51 ET | 23880 | 3.44 |
10:53 ET | 1900 | 3.44 |
10:55 ET | 24271 | 3.445 |
10:57 ET | 2672 | 3.445 |
11:00 ET | 1900 | 3.445 |
11:02 ET | 1947 | 3.445 |
11:04 ET | 1776 | 3.445 |
11:06 ET | 12380 | 3.4475 |
11:08 ET | 500 | 3.4475 |
11:09 ET | 3652 | 3.44 |
11:11 ET | 711 | 3.445 |
11:13 ET | 19282 | 3.45 |
11:15 ET | 224 | 3.445 |
11:18 ET | 600 | 3.45 |
11:20 ET | 6522 | 3.445 |
11:22 ET | 22475 | 3.45 |
11:24 ET | 929 | 3.445 |
11:26 ET | 7204 | 3.45 |
11:27 ET | 792 | 3.445 |
11:29 ET | 400 | 3.445 |
11:31 ET | 300 | 3.445 |
11:33 ET | 700 | 3.445 |
11:36 ET | 10733 | 3.44 |
11:38 ET | 6795 | 3.44 |
11:40 ET | 7859 | 3.445 |
11:42 ET | 1378 | 3.45 |
11:44 ET | 9642 | 3.45 |
11:45 ET | 30096 | 3.45 |
11:47 ET | 1300 | 3.45 |
11:49 ET | 1800 | 3.445 |
11:51 ET | 4940 | 3.45 |
11:54 ET | 82175 | 3.455 |
11:56 ET | 1225 | 3.455 |
11:58 ET | 5483 | 3.455 |
12:00 ET | 700 | 3.455 |
12:02 ET | 27929 | 3.43 |
12:03 ET | 1017 | 3.43 |
12:05 ET | 85657 | 3.45 |
12:07 ET | 2400 | 3.445 |
12:09 ET | 100 | 3.445 |
12:12 ET | 5847 | 3.435 |
12:14 ET | 300 | 3.435 |
12:16 ET | 10336 | 3.425 |
12:18 ET | 2039 | 3.425 |
12:20 ET | 1858 | 3.425 |
12:21 ET | 6972 | 3.415 |
12:23 ET | 589 | 3.41 |
12:25 ET | 31868 | 3.44 |
12:34 ET | 300 | 3.435 |
12:36 ET | 800 | 3.435 |
12:38 ET | 600 | 3.44 |
12:39 ET | 400 | 3.435 |
12:41 ET | 2188 | 3.44 |
12:43 ET | 16707 | 3.435 |
12:45 ET | 4698 | 3.42 |
12:48 ET | 1900 | 3.42 |
12:50 ET | 100 | 3.42 |
12:52 ET | 300 | 3.42 |
12:54 ET | 200 | 3.42 |
12:56 ET | 430 | 3.42 |
12:57 ET | 300 | 3.425 |
12:59 ET | 15329 | 3.415 |
01:01 ET | 13324 | 3.4 |
01:03 ET | 1381 | 3.395 |
01:06 ET | 1036 | 3.395 |
01:08 ET | 5281 | 3.41 |
01:10 ET | 187 | 3.41 |
01:12 ET | 2996 | 3.42 |
01:14 ET | 300 | 3.42 |
01:15 ET | 700 | 3.42 |
01:17 ET | 5904 | 3.415 |
01:19 ET | 1494 | 3.415 |
01:21 ET | 688 | 3.41 |
01:24 ET | 3739 | 3.4299 |
01:28 ET | 100 | 3.425 |
01:30 ET | 4753 | 3.42 |
01:32 ET | 621 | 3.415 |
01:33 ET | 4597 | 3.405 |
01:35 ET | 631 | 3.405 |
01:37 ET | 1186 | 3.405 |
01:39 ET | 800 | 3.4 |
01:42 ET | 200 | 3.405 |
01:44 ET | 1100 | 3.41 |
01:46 ET | 14726 | 3.4006 |
01:48 ET | 300 | 3.405 |
01:50 ET | 497 | 3.4 |
01:51 ET | 1628 | 3.405 |
01:53 ET | 500 | 3.405 |
01:55 ET | 4748 | 3.41 |
01:57 ET | 700 | 3.42 |
02:00 ET | 600 | 3.42 |
02:02 ET | 700 | 3.42 |
02:04 ET | 5974 | 3.43 |
02:06 ET | 7137 | 3.42 |
02:09 ET | 100 | 3.42 |
02:11 ET | 518 | 3.42 |
02:13 ET | 400 | 3.42 |
02:15 ET | 1300 | 3.42 |
02:18 ET | 2509 | 3.42 |
02:20 ET | 10157 | 3.4101 |
02:22 ET | 774 | 3.415 |
02:24 ET | 2798 | 3.43 |
02:26 ET | 200 | 3.43 |
02:27 ET | 920 | 3.43 |
02:29 ET | 100 | 3.43 |
02:31 ET | 3250 | 3.43 |
02:33 ET | 3651 | 3.44 |
02:38 ET | 5862 | 3.425 |
02:40 ET | 2000 | 3.43 |
02:42 ET | 100 | 3.44 |
02:44 ET | 200 | 3.435 |
02:45 ET | 300 | 3.435 |
02:47 ET | 750 | 3.44 |
02:49 ET | 400 | 3.44 |
02:51 ET | 2519 | 3.44 |
02:54 ET | 990 | 3.44 |
02:56 ET | 45043 | 3.43 |
02:58 ET | 600 | 3.43 |
03:00 ET | 2300 | 3.43 |
03:02 ET | 8684 | 3.44 |
03:03 ET | 400 | 3.44 |
03:05 ET | 600 | 3.44 |
03:07 ET | 1700 | 3.44 |
03:09 ET | 1800 | 3.44 |
03:12 ET | 1675 | 3.435 |
03:14 ET | 1900 | 3.44 |
03:16 ET | 956 | 3.44 |
03:18 ET | 1030 | 3.44 |
03:20 ET | 4164 | 3.44 |
03:21 ET | 2900 | 3.44 |
03:23 ET | 58999 | 3.46 |
03:25 ET | 700 | 3.46 |
03:27 ET | 3400 | 3.46 |
03:30 ET | 33831 | 3.445 |
03:32 ET | 8657 | 3.4499 |
03:34 ET | 431 | 3.445 |
03:36 ET | 21959 | 3.44 |
03:38 ET | 6595 | 3.44 |
03:39 ET | 3811 | 3.44 |
03:41 ET | 1500 | 3.44 |
03:43 ET | 18468 | 3.44 |
03:45 ET | 3826 | 3.435 |
03:48 ET | 2681 | 3.44 |
03:50 ET | 2990 | 3.43 |
03:52 ET | 7043 | 3.43 |
03:54 ET | 7190 | 3.44 |
03:56 ET | 76782 | 3.44 |
03:57 ET | 14947 | 3.44 |
03:59 ET | 230334 | 3.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 855.2M | -10.9x | --- |
89Bio Inc | 863.8M | -4.5x | --- |
Humacyte Inc | 832.4M | -8.3x | --- |
Perspective Therapeutics Inc | 869.9M | -7.6x | --- |
Dianthus Therapeutics Inc | 849.7M | -9.1x | --- |
Cogent Biosciences Inc | 886.3M | -3.7x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $855.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -10.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.